The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation

  • Center for Epidemiology and Health Research (ZEG), 10115 Berlin, Germany. dinger@zeg-berlin.de
  • Berlin Center for Epidemiology and Health Research ROR
  • Syneos Health (Germany) ROR

Contraception, 75(5), 344-354

DOI 10.1016/j.contraception.2006.12.019 PMID 17434015

Abstract

Objectives

The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs. METHODS AND MATERIALS: The European Active Surveillance study (EURAS) was a multinational, prospective, noninterventional cohort study of new users of DRSP, levonorgestrel (LNG) and other progestin-containing OCs. Semiannual follow-up was based on mailed questionnaires, with additional follow-up procedures when needed.

Results

Overall, 58,674 women were followed for 142,475 women-years of observation. Loss to follow-up was 2.4%. Serious adverse and fatal events were rare, and rate ratios were close to unity (1.0). Cox regression analysis of cardiovascular outcomes yielded hazard ratios for DRSP-containing vs. LNG-containing and other OCs of 1.0 and 0.8 (upper 95% confidence limits, 1.8 and 1.3) for venous, and 0.3 and 0.3 (upper 95% confidence limits, 1.2 and 1.5) for arterial thromboembolism, respectively.

Conclusions

Risks of adverse cardiovascular and other serious events in users of a DRSP-containing OC are similar to those associated with the use of other OCs.

Topics

drospirenone oral contraceptive cardiovascular safety EURAS study, venous thromboembolism risk drospirenone versus levonorgestrel OC, European Active Surveillance oral contraceptive prospective cohort, drospirenone containing OC arterial thromboembolism risk comparison, oral contraceptive safety cardiovascular events large cohort study, EURAS multinational prospective noninterventional OC safety outcomes, Dinger EURAS drospirenone oral contraceptive surveillance study, oral contraceptive progestin type cardiovascular adverse events, VTE risk new user oral contraceptive drospirenone levonorgestrel, hormonal contraceptive serious adverse events rate 142000 women-years
PMID 17434015 17434015 DOI 10.1016/j.contraception.2006.12.019 10.1016/j.contraception.2006.12.019

Cite this article

Dinger, J. C., Heinemann, L. A. J., & Kühl-Habich, D. (2007). The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. *Contraception*, *75*(5), 344-354. https://doi.org/10.1016/j.contraception.2006.12.019

Related articles